Back to today’s briefing

Story perspectives

Mounjaro Shows Promise in Reducing Cardiovascular Risks

7/31/2025

27 5

Summary

Story summary

Eli Lilly's Mounjaro has emerged as a strong contender in the fight against cardiovascular risks for Type 2 diabetes patients, proving nearly as effective as Trulicity in a significant trial. With an 8% reduction in major cardiovascular events and a 16% drop in death rates, Mounjaro's promising results could reshape treatment choices and regulatory pathways.

1 of 1

Story summary

Eli Lilly's Mounjaro has emerged as a strong contender in the fight against cardiovascular risks for Type 2 diabetes patients, proving nearly as effective as Trulicity in a significant trial. With an 8% reduction in major cardiovascular events and a 16% drop in death rates, Mounjaro's promising results could reshape treatment choices and regulatory pathways.